Novo Nordisk Asks Fed. Circ. To Save Prandin Patent

Law360, Washington (March 4, 2013, 4:18 PM EST) -- Novo Nordisk A/S urged the Federal Circuit on Monday to reinstate a patent for its diabetes treatment Prandin, saying a lower court had ignored the U.S. Patent and Trademark Office's decision backing the patent and placed too high a burden on the drugmaker to maintain the patent's validity.

Although a Michigan federal court determined that prior art invalidated Novo's patent-in-suit that covers a combination treatment of Prandin and metformin, Novo counsel Mark A. Perry of Gibson Dunn & Crutcher LLP blasted the decision, arguing the lower...
To view the full article, register now.